Skip to main content
. 2023 Oct 3;17(6):1359–1367. doi: 10.1007/s12072-023-10575-0

Fig. 3.

Fig. 3

Cumulative event-free survival of CHD with different treatment (IFN, NA, no therapy) compared with CHB patients with different treatment (IFN, NA, no therapy). Risk-free survival for non-cirrhotic (a) and cirrhotic patients (b). Log rank was described for significant analysis only